VolitionRx Limited reported financial results for the quarter ended June 30, 2026. First-half revenue reached $1.4 million, a 112% increase year-over-year, while second-quarter revenue was approximately $0.4 million. Operating expenses decreased by 32%, resulting in an operating loss of $4.2 million, down 34% from the prior year period. The company raised $5.3 million through equity financing activities during the quarter, including $1.2 million from its at-the-market facility and $4.1 million from a public offering of shares and warrants. Management highlighted ongoing licensing discussions with diagnostic companies and progress on clinical submissions for its Nu.Q platform. VolitionRx Limited is an epigenetics company developing blood-based diagnostic tests for cancer and other diseases.
